Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
180 patients will be enrolled at 20 key oncological centres, the sample size is sufficient
for exploratory analysis.
Observational Model: Case-Only, Time Perspective: Prospective
Percentage of Participants With Objective Response
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR). CR is defined as the disappearance of all target lesions. PR is defined as at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Pfizer CT.gov Call Center
Czech Republic: State Institute for Drug Control